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Abstract | Whole-genome sequencing (WGS) of pathogens is becoming increasingly 
important not only for basic research but also for clinical science and practice. In virology, 
WGS will be important for the development of novel treatments and vaccines and for 
increasing the power of molecular epidemiology and evolutionary genomics. In this Opinion 
article, we suggest that WGS of viruses in a clinical setting will become increasingly important 
for patient care. We give an overview of different WGS methods used in virology and 
summarize their advantages and disadvantages. Although there are only partially addressed 
technical, financial and ethical issues with the clinical application of viral WGS, this technique 
provides important insights into virus transmission, evolution, and pathogenesis.  
 
Since the publication of the first shotgun sequenced genome (cauliflower mosaic virus1), the 
draft human genome2 and the first bacterial genomes (Haemophilus influenzae3 and 
Mycoplasma genitalium3) and enabled by the rapidly falling cost of high-throughput 
sequencing4, genomics has changed our understanding of human and pathogen biology. Several 
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large projects that aim to systematically analyse microbial genomes have been recently 
completed or are on-going (for example, sequencing thousands of microbiomes5 and fungal 
genomes5,6); these projects are shaping our knowledge of the genetic variation present in 
pathogen populations, the genetic changes that underlie disease, and the diversity of 
microorganisms with which we share our environments. 
The methods and data from whole-genome sequencing (WGS), which have been developed 
through basic scientific research, are increasingly being applied to clinical medicine, involving 
both humans7 and pathogens. For example, WGS has been used to identify new transmission 
routes of Mycobacterium abscessus8 in healthcare facilities (nosocomial transmission) and to 
understand Neisseria meningitidis epidemics in Africa9, whereas sequencing of partial 
genomes has been used to detect drug resistance in RNA viruses such as influenza virus10 and 
DNA viruses such as human cytomegalovirus (HCMV)11. Viral genome sequencing is 
becoming ever more important, above all in clinical research and epidemiology. WGS of 
pathogens has the advantage of detecting all known drug resistance variants in a single test, 
whereas deep sequencing (that is, sequencing at high coverage) can identify low levels of drug 
resistance variants to allow intervention before resistance becomes clinically apparent12,13. 
Whole genomes also provide good data with which to identify linked infections for public 
health and infection control purposes14,15. However, progress in using viral WGS for clinical 
practice has been slow. By contrast, WGS of bacteria is now well accepted particularly for 
tracking outbreaks and for the management of nosocomial transmission of antimicrobial 
resistant bacteria16,17.  
In this Opinion article, we will address the challenges and opportunities for making WGS, 
using modern next generation sequencing (NGS) methods, standard practice in clinical 
virology. We will discuss the strengths, weaknesses and technical challenges of different viral 
WGS methods (Table 1) and the importance of deeply sequencing some viral pathogens. We 
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will also explore two areas in which viral WGS has recently proven its clinical utility: 
metagenomic sequencing to identify viruses causing encephalitis (Box 1); and role of WGS in 
molecular epidemiology and public health management of the pan-American Zika virus 
outbreak (Box 2). Finally, we will briefly consider the ethical and data analysis challenges that 
clinical viral WGS presents. 
 
[H1] Why sequence viruses in the clinic?  
For small viruses such as human immunodeficiency virus (HIV), influenza virus, hepatitis B 
virus (HBV) and hepatitis C virus (HCV), sequencing of partial genomes has been widely used 
for research, but it also has important clinical applications. One of the main applications and 
reasons to sequence viruses is the detection of drug resistance. For example, the management 
of highly active antiretroviral therapy (HAART) for HIV relies on viral sequencing for the 
detection of drug resistance variants. HAART has dramatically improved survival of patients 
with HIV, but successful therapy requires long-term suppression of viral replication with 
antiretroviral drugs, which may be prevented by impaired host immunity, sub-optimal drug 
penetration in certain tissue compartments and incomplete adherence of patients to therapy18. 
When viral replication continues despite treatment the high mutation rate of HIV enables 
resistance variants to develop. It has become standard practice in many parts of the world to 
sequence the HIV pol gene, which encodes the main viral enzymes, to detect variants that 
confer resistance to inhibitors of reverse transcriptase, integrase or protease19, particularly 
when patients are first diagnosed and when viral loads indicate treatment failure. Sequencing 
resistance variants has allowed targeted changes in treatment, and this has resulted in greater 
reductions in virus loads compared with standard care (undetectable HIV load in 32% vs 14% 
of patients after six months)20,21. Thus, sequencing resistance variants to guide HIV treatment 
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improves disease outcomes. Similar approaches have been used to identify resistance variants 
in HCV22, HBV23, and influenza virus24. 
 
[H1] Why sequence whole genomes? 
Limited sequencing of the small number of genes that encode targets of antiviral agents, such 
as HIV pol, has been the norm in clinical practice. For detecting a limited number of antiviral 
resistance variants, WGS has been too costly and labour-intensive to use as compared with 
sequencing only the specific genes targeted by the drugs. However, the increasing numbers of 
resistance genes that are located across viral genome, together with falling costs of sequencing 
and the use of sequence data for transmission studies, are driving a reappraisal of the need for 
WGS. For example, antiviral treatment for HCV now targets four gene products (NS3, NS4A, 
NS5A, NS5B) and these genes encompass more than 50% of the viral genome25. Individually 
sequencing each of these genes can be as expensive and time-consuming as WGS26. Partial 
genome sequencing is particularly problematic for large viral genomes, in particular those of 
the herpesviruses HCMV11, varicella zoster virus (VZV)27, herpes simplex virus type 1 (HSV-
1)28 and HSV-229. These viruses have traditionally been treated with drugs targeting the viral 
thymidine or serine-threonine protein kinases and DNA polymerase. However, the growing 
numbers of drugs in development that interact with different proteins encoded by viral genes 
scattered across the genome, means that targeted sequencing for resistance testing is costly, 
involves more PCR reactions increasing the chance of failure, requires more starting material, 
is more labour intensive and generally less tractable for diagnostic use30. Sequencing the whole 
genome simultaneously captures all resistance variants and obviates the need to design and 
optimise PCR assays for detecting resistance to new drugs. A good example of this is HCMV, 
for which WGS can simultaneously capture the genes that encode targets of licensed therapies, 
such as UL27 (unknown function), UL54 (DNA polymerase), and UL97 (serine-threonine 
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protein kinase), and of newer drugs, such as letermovir, which targets UL56 (terminase 
complex). This enables comprehensive anti-viral resistance testing in a single test11. At the 
same time WGS can provide information on antigenic epitopes, viral evolution within a patient 
over time11, and evidence of recombination between HCMV strains31. WGS can also detect 
putative novel drug resistance variants and predict changes to epitopes although phenotypic 
testing of variants is required to confirm clinical resistance32 and to map epitope changes33.  
As pre-existing resistance to antiviral drugs increases (for example, HCV that is resistant to 
protease inhibitors34 and HBV that is resistant to nucleoside analogue reverse-transcriptase 
inhibitor 35), WGS will provide the comprehensive resistance data required for selecting 
appropriate treatment. The complete knowledge of all resistance variants can also support novel 
clinical management decisions; for example, identification of extensive genome-wide HCMV 
drug resistance within a patient supported the decision to treat the patient with autologous 
cytomegalovirus-specific T cells instead of antivirals36.  
WGS may also better identify transmission events and outbreaks, which is not always possible 
with sequences of sub-genomic fragments. For example, WGS of respiratory syncytial virus 
(RSV) identified variation outside the gene that is traditionally used for genotyping, and such 
information could be used to track outbreaks within households, when the genetic variability 
in single genes is too low for transmission studies37. The high number of phylogenetically 
informative variant sites that can be obtained from full-length or near full-length genomes 
obviates the need for high quality sequences, which allowed robust linking of Ebola cases and 
public health interventions in real time during the 2015 epidemic38. Another example of WGS 
supporting public health efforts is Zika virus (Box 2).  
Using pathogen WGS routinely for diagnostic purposes39 is likely to have wider clinical and 
research benefits. For example, Zika sequences generated for epidemiological purposes been 
used to inform public health decisions40, whilst HIV genomes sequenced to identify antiviral 
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resistant variants have also be used to study viral evolution41 and viral genetic association with 
disease, including genotype-phenotype association studies and genome-to-genome association 
studies, which look for associations between viral genetic variants, host genetic variants and 
outcomes of infection, such as viral load set point in HIV infection42,43.  
 
[H1] Why do we need deep sequencing?  
Modern methods, which make use of massively parallel sequencing, allow better examination 
of diversity and analysis of viral populations that contain nucleotide variants or haplotypes at 
low frequencies (less than 50% of the consensus sequence). Minority variant analysis is 
particularly powerful for RNA viruses, retro-transcribing DNA viruses and retroviruses, 
because they typically show high diversity, even in a single host. HIV is the classic example; 
the HIV reverse transcriptase is error-prone and introduces mutations at an extremely high rate 
(4.1 ± 1.7 × 10−3 per base per cell)44. Not one, but many closely related but subtly different 
viral variants, exist in a single patient. These variants are sometimes described as a quasispecies 
or a cloud of intra-host viral diversity. The presence of a mixed population of viruses introduces 
problems for determining the true consensus ‘majority’ sequence, but these minority (non-
consensus) variants may also change the clinical phenotype of the virus, and can predict 
changes in genotype, tropism or drug resistance. For example, a minor variant conferring drug 
resistance in HIV present at only 2.1% of sequencing reads in a patient at baseline can rapidly 
become the majority (consensus) variant under the selective pressure of drug treatment45. 
Similar changes in frequency of resistance-associated alleles during treatment have been 
observed for HBV46, HCV47, HCMV11 and influenza virus48.  
Deep-sequencing of viruses is not only required to detect drug resistance: it is also key for 
genotypically predicting the receptor tropism of HIV, which has treatment implications. HIV 
can be grouped by its cellular co-receptor usage as R5 (C-C chemokine receptor type 5 (CCR5)-
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using), X4 (C-X-C chemokine receptor type 4 (CXCR4)-using) or R5X4 (dual tropism). 
Maraviroc is a CCR5 antagonist, which blocks infection of R5-tropic HIV, but not of X4 and 
R5X4 HIV. Just a 2% frequency of X4 or R5X4 genotypes is predictive of maraviroc treatment 
failure49. Sub-consensus frequencies of X4 or R5X4 HIV are also important for the success50 
and failure51 of bone marrow transplants from CCR5-deficient (CCR5-Δ32) donors and this 
information may influence the decision to stop antiviral therapy in these patients50.  
Minority variants and identification of haplotypes can also be used to detect mixed infections. 
Infections with different HCMV genotypes or super-infections52 are associated with poor 
clinical outcomes and detection of such mixed infections by WGS might justify more 
aggressive treatment. 
Sanger sequencing of a virus population can detect minority variants at frequencies of between 
10 and 40%53, whereas NGS can sequence those same PCR amplicons to a much greater 
depth54, and consequently capture more of the variability present. Sensitivity and specificity 
are specific for the analysed virus and the sequencing method. Many studies of HIV drug 
resistance that use deep-sequencing of PCR amplicons require minority variants to be present 
at >1%, to reduce the possibility of false positives55,56. This may miss drug resistance mutations 
at frequencies of 0.1%-1% and lead to poor treatment outcome56. Although a 1-2% frequency 
threshold (or lower) may be clinically relevant to detect drug resistance in HIV, it is less clear 
whether the same degree of sensitivity is required for monitoring vaccine escape in HBV or 
drug resistance in herpesvirues (discussed below). Large cohorts of patients will need to be 
tested before, during and after treatment45,49 to establish thresholds for minority drug 
resistance11 and vaccine escape variants that are clinically relevant for each virus.  
Direct deep sequencing of clinical material, either by shotgun or RNAseq methods (so called 
metagenomic methods), also allows the unbiased detection and diagnosis of pathogens and 




[H1] Practical considerations 
Sequencing viral nucleic acids, whether from cultures or directly from clinical specimens, is 
complicated by the presence of contaminating host DNA57. By contrast, most bacterial 
sequencing is currently performed on clinical isolates (i.e. cultured), thus sample preparation 
is comparatively straightforward (Table 2 and reviewed elsewhere58). Currently, genome 
sequencing of viruses can be achieved by ultradeep sequencing or by enriching for viral nucleic 
acids before sequencing, either directly or by concentrating viral particles. All these approaches 
have their own costs and complexities.  
 
Three main methods are currently used for viral genome sequencing: metagenomic sequencing, 
PCR amplicon sequencing and target enrichment sequencing (Figure 1). 
 
[H3] Metagenomics. Metagenomic approaches have been extensively used for pathogen 
discovery and for characterising microbial diversity in environmental and clinical samples59,60. 
Total DNA and/or RNA, including from host, bacteria, viruses, fungi and other pathogens, are 
extracted from a sample, a library is prepared and sequenced by ‘shotgun’ or RNA-seq. Box 1 
explores the diagnostic applications for metagenomics and RNAseq, for example in 
encephalitis of unknown aetiology61-63, for which conventional methods such as PCR often are 
not diagnostic whereas metagenomics and RNAseq have detected viral infections64,65,66 and 
other causes67 of encephalitis. In addition, these methods have been used to sequence some 
whole viral genomes, including Epstein-Barr virus (EBV)68 and HCV26. However, the presence 
of contaminating nucleic acids from the host and commensal microorganisms57 (Table 2) in 
clinical specimens reduces sensitivity. The proportion of reads matching the viral target 
genome from metagenomic WGS is often low; for example, 0.008% for EBV in the blood of a 
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healthy adult69, 0.0003% for lassa virus in clinical samples70 and 0.3% for Zika virus in a 
sample that was enriched for viral particles by filtration and centrifugation71. The read depth is 
often inadequate to detect resistance26 and the cost is high. Thus metagenomic sequencing has 
typically only been performed on a small number of samples for research purposes71,72. 
Concentration of viral particles (see Zika virus example above71), depletion of host material 
and/or sequencing to high read depth can increase the amount of viral sequence, but all of these 
methods add to the cost. Concentrating viral particles from clinical specimens by antibody-
mediated pulldown (for example virus discovery based on cDNA-AFLP (amplified fragment 
length polymorphism); VIDISCA), filtration, ultracentrifugation, and depletion of free nucleic 
acids, which mostly come from the host have all been tried73-76; however, these methods may 
also reduce the total amount of viral nucleic acids so that it is insufficient for preparing a 
sequencing library. Non-specific amplification methods, such as multiple displacement 
amplification (MDA), which make use of random primers and phi 29 polymerases, can increase 
the DNA yield. However, these approaches are time consuming, costly, and may increase the 
risk of biases, error and contamination without necessarily improving sensitivity77,78. 
Moreover, the proportion of host reads often remains high79.  
When metagenomic methods are used for pathogen discovery or diagnosis, it is critical to have 
appropriate bioinformatic tools and databases that can evaluate whether detected pathogen 
sequences are likely to be the cause of infection, incidental findings or contaminants. 
Bioinformatic analyses of large metagenomic datasets require high-performance computational 
resources.  
The fact that metagenomics requires no prior knowledge of the viral genome, can be considered 
an advantage26 as it allows novel viruses to be sequenced without the need for primer or probe 
design and synthesis. This is particularly relevant for rapid responses to emerging threats such 
as Zika virus80. For virus-associated cancers, metagenomics can inform clinical care, provide 
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information on cancer evolution and generate high coverage data of integrated virus genomes68. 
However, incidental findings, both in host and microbial sequences, may also present ethical 
and even diagnostic dilemmas for clinical metagenomics81 (see below). A recent example was 
a cluster of cases of acute flaccid myelitis that were associated with enterovirus D6882. The 
metagenomic data from patient samples showed the presence of alternative pathogens, some 
of which are treatable, and was debated in formal83 and informal scientific channels 
(http://omicsomics.blogspot.co.uk/2015/07/leaky-clinical-metagenomics-pipelines.html). 
Regulation and reporting frameworks will be important to resolve future issues of this kind. 
 
[H3] PCR amplicon enrichment. An alternative to metagenomic approaches is to enrich the 
specific viral genome before sequencing. PCR amplification of viral genetic material using 
primers that are complementary to a known nucleotide sequence has been the most common 
approach for enriching small viral genomes such as HIV and influenza virus. Recent examples 
of PCR amplicon enrichment followed by WGS include phylogenetic analysis of a measles 
virus outbreak at the 2010 Winter Olympics84 and tracking the recent Ebola virus38 and Zika 
virus (Box 2) epidemics. PCR amplicon WGS of norovirus, which has a genome size of 7.5kb, 
has been used to understand transmission in community85 and hospital86 settings, which 
revealed both independent introductions of the pathogen to the hospital and nosocomial 
transmission despite measures to control infection86. Other PCR-based deep sequencing studies 
have generated multiple whole genomes of influenza virus87 (~13.5kb), dengue virus88 (~11kb), 
and HCV89 (9.6kb). This was feasible because these viruses all have relatively small genomes, 
requiring only few PCR amplicons to assemble whole-genome sequences. However, the 
heterogeneity of RNA viruses, such as HCV26, norovirus85, rabies virus90 and RSV37 may 
necessitate the use of multiple overlapping sets of primers to ensure amplification of all 
genotypes. PCR amplicon sequencing is more successful for WGS from samples with low virus 
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concentrations than metagenomic methods26, although other methods such as target enrichment 
of viral sequences may work equally well in such samples, as shown for norovirus samples91. 
Overlapping PCRs combined with NGS have been used to sequence the whole genomes of 
larger viruses such as HCMV92, but this method has limited scalability, as many primers and a 
relatively large amount of starting DNA are needed92. This limits the number of suitable 
samples available and also the genomes which can be studied with this method. For example, 
8 to 19 PCR products were needed to amplify the genome of Ebola virus38, and two studies of 
norovirus needed 14 and 22 PCR products respectively85,86. For clinical applications this is 
problematic because of the high laboratory workload associated with large numbers of discrete 
PCR reactions, the necessity for individually normalising concentrations of different PCR 
amplicons prior to pooling, the increasing probability of reaction failure due to primer 
mismatch, particularly for very variable viruses, and the high costs of labour and 
consumables93. Therefore, although PCR-based sequencing of viruses as large as 250 Kb is 
technically possible, the proportional relationship between genome size and technical 
complexity make PCR-based sequencing of viral genomes beyond 20 - 50 Kb impractical with 
current technologies, particularly for large multi-sample studies or routine diagnostics. Another 
consideration is that increasing numbers of PCR reactions require a corresponding increase in 
sample amount, and this is not always possible as clinical specimens are limited. Improvements 
in microfluidic technologies may help to overcome some of these barriers, for example 
Fluidigm, RainDance and other ‘droplet’ sequencing technologies. Microfluidics-based PCR 
and pooling of multiple amplicons have been used successfully to sequence multiple 
antimicrobial resistance loci, for example from the microbiome of pigs94, and can also be used 
for viral genomes, potentially down to the single-genome level 95.  
Highly variable pathogens, particularly those with widely divergent genetic lineages or 
genotypes, such as HCV96 and norovirus cause problems for PCR amplification, such as primer 
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amplification26,91 and primer mismatches85. Careful primer design may help to mitigate these 
problems, but novel variants remain problematic. 
 
[H3] Target enrichment. Methods of target enrichment (also known as pulldown, capture or 
specific enrichment methods) can be used to sequence whole viral genomes directly from 
clinical samples without the need for prior culture or PCR97-99. These methods typically involve 
small RNA or DNA probes that are complementary to the pathogen reference sequence (or 
panel of reference sequences). Unlike in specific PCR amplicon-based methods, the reaction 
can be carried out in a single tube that contains overlapping probes that cover the whole 
genome. In a hybridisation reaction, the probes, which are bound to a solid phase (for example, 
streptavidin-labelled magnetic beads) capture or ‘pull down’ complementary DNA sequences 
from the total nucleic acids present in a sample. Capture is followed by sequencer-specific 
adaptor ligation and a small number of PCR cycles to enrich for successfully ligated fragments. 
This has been used successfully to characterise small and large, clinically relevant viruses such 
as HCV26, HSV1100, VZV99, EBV101, CMV68, human herpesvirus 6 (HHV6)102 and HHV7103. 
The reaction is performed in a single well and, like microfluidics-based PCR, is amenable to 
high throughput automation101. The lack of a culture step means that the sequences obtained 
are more representative of original virus than cultured viral isolates, and there are fewer 
mutations than in PCR amplified templates68,99. The success of this method depends on the 
available reference sequences for the virus of interest: specificity increases when probes are 
designed against a larger panel of reference sequences, as this leads to better capture of the 
diversity within and between samples. Target enrichment is possible despite small mismatches 
between template and probe, but, whereas PCR amplification requires only knowledge of 
flanking regions of a target region, target enrichment requires knowledge of the internal 
sequence to design probes. However, if one probe fails, internal and overlapping regions may 
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still be captured by other probes68,99. Target enrichment is not suitable for characterisation of 
novel viruses with low homology to known viruses, for which metagenomics and in some 
cases, PCR using degenerate primers, which are a mix of similar but variable primers, may be 
more appropriate. 
As with all methods, the technique is constrained by starting viral concentration. Although 
virus could be sequenced from samples with viral loads as low as 2000 International Units 
(IU)/ml (HCV) or 2500 IU/ml (HCMV), there was reduced depth of coverage in sequencing 
data at lower viral concentration26,68. With metagenomics, the proportion of sequencing data 
mapping to the pathogen from unenriched of clinical samples is small. Target enrichment can 
increase the percentage of on-target viral reads from 0.01% up to 80% or more68. The 
improvement in quality and depth of sequence that results allows more samples to be sequenced 
per run compared to unenriched metagenomic libraries for equivalent on-target sequencing 
performance, and decreases the price of sequencing, although the cost of library preparation is 
increased. There are alternative approaches for enriching viral reads, including pulse-field gel 
electrophoresis104, which separates large viral genomes from smaller fragments of host DNA 
fragments. 
Enrichment techniques that use degenerate RNA or DNA probes to capture hundreds of viral 
species, for example, VirCapSeq105, have also been developed. This method is designed for 
detection of both known and novel viruses, although its performance remains to be evaluated. 
 
[H3] Comparison of methods. To date, there has been very little direct comparison between 
the three methods for viral genome sequencing in clinical practice, with only one paper 
evaluating relative performance for HCV sequencing26. Results from this study, in which three 
different enrichment protocols, two metagenomic methods and one overlapping PCR method 
were evaluated, showed that metagenomic methods were the least sensitive, yielded the lowest 
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genome coverage for comparable sequencing effort and were more prone to result in 
incomplete genome assemblies. The PCR method required repeated amplification and was the 
most likely to miss mixed infections, but when reactions were successful, it resulted in the most 
consistent read depth, whereas read depth was proportional to virus copy number in 
metagenomics and target enrichment. PCR, compared to metagenomics and target enrichment, 
generated more incomplete sequences for some HCV genotypes (particularly genotype 2). 
Target enrichment was the most consistent method to result in full genomes and identical 
consensus sequences. The ease of library preparation for metagenomic and target enrichment 
sequencing of HCV was considered a major advantage for clinical applications, but PCR may 
still be appropriate for very low virus load samples. 
Similar results were achieved in a study that compared norovirus PCR amplicon and target 
enrichment sequencing of norovirus91. With target enrichment, the whole viral genome could 
be sequenced in 164/164 samples, whereas PCR-based capsid sequencing was only possible in 
158/164 samples, owing to low virus titres and PCR primer mismatches, which suggests that 
target enrichment is more sensitive than PCR for norovirus sequencing and better 
accommodates between-strain sequence heterogeneity91. Target enrichment has also been used 
for samples with low virus loads and incomplete genome coverage in metagenomic 
sequencing106. Both metagenomics and target enrichment can be used for pathogen genomes 
of all sizes, whereas PCR-based methods are less suitable for large viral genomes or for non-
viral (that is, bacterial, fungal and parasite) genomes. 
Direct comparisons of different methods26,91 will be important for determining when each 
method should be used, based on sensitivity and specificity, as well as factors such as cost, 





[H1] Analysis and interpretation challenges  
Beyond the technical challenges of viral WGS that are mentioned above, there are a number of 
other roadblocks which may slow the advance of WGS in the clinic. They may be considered 
in three groups: ethical issues, including incidental host and microbiological findings; 
regulatory issues, such as the establishment of standards, good laboratory practice and 
sensitivity and specificity thresholds for sequencing; and analytical issues regarding data 
interpretation and the numerous choices of analysis options. 
 
[H3] Ethical issues and incidental findings. In many clinical tests (for example, MRI scans and 
sequencing of the patient’s genome), there is a risk of detecting a disease association that was 
not part of the original investigation but might be of clinical importance for the individual or 
their family. These incidental findings remain a topic of intense medical ethical debate107. The 
risk of incidental findings in pathogen sequencing (for example, the discovery of HIV infection 
during metagenomic sequencing for other pathogens) is not novel and the solution in clinical 
virology laboratories that use multiplex PCRs is to suppress results that have not been requested 
(personal communication, J.B.). In the UK, the clinical virologist who interprets the test results 
is part of the team managing the patient and as such may decide to discuss an unexpected result 
with the physician-in-charge. Incidental host genetic findings (for example, detection of 
variants that predispose to cancer development) in a pathogen metagenomic analysis are not 
reported to the individual in the UK, because this is only permissible with patient consent. In 
regard to both host and virus incidental findings, target enrichment and PCR have the advantage 
of only providing results about pathogen of interest. The ethical and privacy concerns 
associated with the presence of host genetic data in publically available metagenomic datasets 




[H3] Regulatory challenges. Regulation, as well as helping to address some of the ethical 
concerns, will also be important in standardising WGS of viruses. The framework required to 
make viral WGS sufficiently robust and reproducible in clinical practice will come from a 
number of areas.  
The framework of laboratory accreditation and benchmark testing already available (for 
example Clinical Laboratory Improvement Amendments of 1988 (CLIA) regulations in the 
USA, or accreditation according to medical laboratory quality and competence standardisation 
criteria for ISO 15189) will support the development of viral WGS standards, if there is 
sufficient need and pressure from hospitals, journals and funding agencies to implement 
clinical viral WGS. 
Lessons learned from the use of PCR in diagnostics may be useful here, beginning with 
ensuring good clinical laboratory and molecular practices108,109. This will mean including 
negative samples in every sequencing run to assess contamination thresholds, spiking samples 
with a known virus to provide a sensitivity threshold and including positive controls and 
controls for batch-to-batch variation110, all of which will increase sequencing costs and are 
likely to deter adoption of pathogen genome sequencing by laboratories, that are sequencing 
only small batches of samples. Centralisation of virus WGS can help to ensure keeping 
adequate standards, processing of large batches of samples and reducing costs.  
The issues of sensitivity and contamination are especially important in WGS because of the 
risk of both false-negative and false-positive detection of pathogens. Highly sensitive 
sequencing (whether metagenomic, PCR-based or target enrichment-based) may detect low-
level contaminating viral nucleic acids111,112. For example, murine leukaemia virus113,114 and 
parvovirus-like sequences115,116 are just two of many contaminants that can come from 
common laboratory reagents such as nucleic acid extraction columns117. As with other highly 
sensitive technologies, robust laboratory practices and protocols are needed to minimize 
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contamination. It is also important to remember that detection of viral nucleic acid does not 
necessarily identify the cause of illness, and it is good practice when using NGS methods for 
diagnosis of viral infections to confirm the findings with alternative, independent methods 
which do not rely on testing for nucleic acids. For example, in cases of encephalitis of unknown 
origin, positive NGS findings can be confirmed by immunohistochemical analysis of the 
affected tissue64,118, or identification of the virus by electron microscopy or tissue culture81.  
The standardisation of methods, including bioinformatics, will be key to the success of NGS 
and WGS in clinical virology. Software packages that use a graphical user interface (GUI) are 
preferable to tools that require command-line expertise. Strict version control of software and 
analysis pipelines is needed to make results reproducible, to make best practices easily 
shareable, and to allow accreditation of analysis software. However, best-practice analysis 
methods are continually evolving and prematurely standardising in an overly rigid manner may 
inhibit innovation. Commercialisation and regulation may help, as they provide financial and 
regulatory incentives to ensure that analysis tools and technologies meet the clinical needs. 
Finally, the development of well curated databases that show which variants are truly indicative 
of drug resistance will be critical for accurate clinical interpretation. Such databases have 
already been created for HIV119, HBV120,121 and HCV122, but without recognition of their value 
by funding agencies, and corresponding centralised funding to ensure their continued 
maintenance and upkeep, these databases and associated tools may become swiftly outdated or 
unusable. 
 
[H3] Financial barriers to the clinical use of viral WGS. Although there are good reasons for 
sequencing whole genomes and, in general, for using NGS, if diagnostic or hospital-based 
laboratories are to be persuaded to transition away from sequencing sub-genomic fragments, 
they need to see the benefit of the additional information for patient care and the practical 
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feasibility of WGS. This includes WGS workflows that are as scalable and automatable as sub-
genomic fragment sequencing, a suitable regulatory framework and a price for sequencing 
whole genomes that is competitive with sequencing fragments.  
Currently, the cost of sequencing viral genomes, despite their small size, remains higher than 
the cost of sequencing sub-genomic resistance genes. The cost difference between sequencing 
a target region and the whole virus genome is largely governed by the size of the genome versus 
the size and number of target loci. Additionally, whole genome information may provide 
important additional knowledge, as discussed above. 
 
[H1] What does the future hold? 
Current generation NGS technologies based around Illumina, 454, Ion Torrent or Sanger 
methodologies all generate short-read data, which presents challenges for haplotype phasing, 
i.e. determining whether genetic variants (whether inter or intra-host) occur on the same genetic 
background (single viral genome, clonal) or on related, highly-similar but different genetic 
backgrounds within the same population (sometimes called a viral swarm or cloud). 
Furthermore, repetitive regions and recombination are more difficult to resolve using short 
reads owing to problems such as mapping ambiguities. The clinical implications of 
understanding whether, for example, multi-drug resistance variants occur together on a single 
viral genome or distributed between a mixed population of viruses, each with different drug 
resistance profiles, is currently unclear.  
Although there are computational tools123 to help resolve these issues, new technologies can 
generate longer reads. Newer, single-molecule sequencers such as PacBio (Pacific 
Biosciences) and MinION (Oxford Nanopore) are capable of extremely long-read sequencing, 
and whole viral genomes (for example viruses with genomes under 20kb, such as Ebola virus, 
norovirus and influenza A virus) could theoretically be obtained from single reads. MinION 
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also has the advantage of being very fast, taking as little as four hours to go from sample receipt 
to reporting of analysed data124. So far, viral read lengths achieved by MinION sequencing 
have been relatively modest; examples of mean read lengths are 751bp  for modified Vaccinia 
Ankara virus, 758bp for cowpox virus125, 455bp (range 126–1477bp) for chikungunya virus, 
358bp (range 220–672bp) for Ebola virus, 1576bp126 (personal communication M.A.B: 
6895bp) for HCMV and 572bp (range 318–792bp) for HCV127. Results from the better-
established PacBio technology are more promising, including a recent report of a mean read 
length of 12,777bp for pseudorabies virus128, which has a double-stranded DNA genome 
~142kp in length. 9.2kb reads have been achieved with PacBio for HCV, although 9.2kb of the 
9.6kb genome had been pre-amplified by PCR129.  
A drawback of both NGS and single-molecule sequencing is the need for high coverage to 
minimize the impact of sequencing errors. This is particularly problematic for drug resistance 
studies, as drug resistance most frequently results from single nucleotide mutations or small 
deletions (1-3 bases), especially in lower-fidelity RNA viruses130. Achieving the high coverage 
necessary to ensure accurate variant typing is challenging when there is a lot of host DNA 
compared to viral sequences, and when the error profile of a technology makes point mutations 
particularly hard to detect124. At the time of writing, MinION sequencing (R9 pore chemistry) 
has raw high quality (so called '2D reads') read error rates of ~5% (personal communication, 
Josh Quick), which compares unfavourably with error rates of other technologies (Illumina 
(<0.1%), Ion Torrent (~1%), but not PacBio (13% single pass)131, although accuracy can been 
improved using circular consensus read sequencing132,133.  
However, combining these long-read technologies with target enrichment provides a potential 
way forward126,134, as ambiguities can be resolved if sufficient depth of sequence is achieved 
for the target pathogen, and error rates for all methodologies may be reduced by further 
technological and analytical improvements. Depleting the host nucleic acids is an alternative 
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solution, as a higher proportion of virus reads would be recovered from each sequencing run. 
Whereas there are already solutions in place to achieve this for bacterial sequencing (for 
example, depletion of human ribosomal RNA or mitochondria and selective depletion of DNA 
with a certain methylation pattern), no similar methods exist so far for viral sequencing. 
 
[H1] Conclusions 
Viral WGS is of growing clinical importance for diagnosis, disease management, molecular 
epidemiology and infection control. There are a number of methods available to achieve WGS 
of viruses from clinical samples; amplicon sequencing, target enrichment or metagenomics. 
Currently the choice of method is specific to both the virus and the clinical question. 
Metagenomic sequencing is most appropriate for diagnostic sequencing of unknown or poorly 
characterised viruses, PCR amplicon sequencing works well for short viral genomes and low 
diversity in primer binding sites, and target enrichment works for all pathogen sizes, but is 
particularly advantageous for large viruses and for viruses with diverse but well characterised 
genomes. Two obvious areas of innovation currently exist: methods that can effectively deplete 
host DNA without affecting viral DNA and further development of long-read technologies to 
achieve the flexibility and competitive pricing of short-read technologies. New technologies 
are needed to unite the strengths of these different methods and allow healthcare providers to 
invest in a single technology that is suitable for all viral WGS applications.  
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Box 1. RNA-seq and metagenomic diagnostics. 
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In cases of encephalitis of unknown origin, metagenomic techniques are promising diagnostic 
tools. There are a variety of protocols in use, but the main methods used are RNA-seq and 
metagenomics. For RNA-seq, the total RNA or a subset of RNA is extracted from a sample 
(cerebrospinal fluid or brain biopsy, for example), converted to cDNA and sequenced. 
Metagenomics generally describes the same procedure for DNA, but may also include 
simultaneous sequencing of DNA and RNA by incorporating a cDNA synthesis step. RNA-
seq may improve detection of pathogenic viruses, as many viruses have RNA genomes and 
viral mRNAs in the cerebrospinal fluid (CSF) or brain indicate both the presence of the virus 
and which viral genes are being transcribed. However, DNA viruses which experience low-
level transcription may be poorly detected using RNA-seq and read numbers for DNA viruses 
may be higher in metagenomic datasets62. 
Both methods have successfully identified new or known viral pathogens in encephalitis of 
unknown origin. Metagenomics has been used to aid the diagnosis and characterisation of 
enterovirus D68 in cases of acute flaccid paralysis82. Metagenomics identified herpesviruses in 
the CSF of four patients with suspected viral meningoencephalitis135. RNA-seq also identified 
HSV1 in an encephalitis case, although the use of a DNAse I digestion (intended to lower the 
amount of host nucleic acid) reduced the number of HSV1 reads62. Mumps vaccine virus has 
also been detected a chronic encephalitis case using RNAseq136 .  
RNA-seq has been very successful in identifying encephalitis caused by astroviruses137,138 and 
coronaviruses64. The deaths of three squirrel breeders from encephalitis was linked to a novel 
squirrel bornavirus, which was identified by separate metagenomic sequencing of DNA and 
RNA61. Metagenomics provides more information about the virus in a sample than PCR alone, 
which may be important for molecular epidemiology, whereas RNA-seq can identify viral 




Box 2: WGS of Zika virus 
Whole-genome sequencing (WGS) of Zika virus can help to understand the epidemiology of 
the outbreak, including the origin and spread of the virus, and the connection between the virus 
and microcephaly. It also informs control measures, such as stopping importation of cases or 
interrupting transmission from a reservoir, and blood safety measures in hospitals.  
For flaviviruses, such as Zika virus, WGS or at least near whole-genome sequencing is required 
to give molecular epidemiology studies sufficient power40. WGS, phylogenetic analysis and 
molecular clock dating, combined with other epidemiological data, were useful to study the 
introduction of Zika virus to South America40. For example, the most recent common ancestor 
of strains circulating in Brazil predates the 2014 football World Cup, making it highly unlikely 
that this event was responsible for introducing Asian-lineage Zika virus to South America40. 
WGS is also central for understanding Zika virus pathogenesis, for example, by trying to 
identify sequence changes that are associated with microcephaly, as it’s currently unclear 
which genome regions determine pathogenesis. It is likely that numerous whole genome 
sequences of Zika virus from around the world and from microcephaly and asymptomatic cases 
are needed to link particular mutations to birth defects. So far, no changes in the Zika virus 
genome have been unambiguously associated with microcephaly40,71,80. 
WGS and fragment sequencing were used to identify a case of Zika virus transmission through 
platelet transfusion139. This case suggested that asymptomatic donors can transmit the virus to 
immunocompromised individuals. PCR-based testing had already established the presence of 
Zika virus in the blood supply in a previous outbreak, but no infection was detected in recipients 
of blood products140. Based on this new case, blood products may need to be screened routinely 
for Zika virus139.  
Finally, WGS of Zika virus isolates has identified sequence polymorphisms in primer-binding 
sites141, which may make PCR-based diagnosis and virus load quantification more difficult. 
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This highlights the need to characterise population-level diversity, especially in epidemics, in 
which the locally circulating virus may have diverged from viruses from other locations or time 
periods. A number of projects are underway to determine population-level diversity, including 
the Zika in Brazil real time analysis (ZIBRA) mobile laboratory project142, which uses portable 
metagenomic sequencing of Zika virus and real-time reporting of results106. 
 
Figure 1: Methods for sequencing viral genomes from clinical specimens.   
All specimens originally comprise a mix of host (in blue) and pathogen (in red) sequences. 
Direct metagenomic sequencing provides an accurate representation of the sequences within 
the sample although at high sequencing and data analysis/storage costs. PCR amplicon 
sequencing uses many discrete PCR reactions to enrich the viral genome, which increases the 
workload for large genomes substantially, but reduces the costs. Target enrichment 
sequencing uses virus-specific nucleotide probes bound to a solid phase, such as beads, to 
enrich the viral genome in a single reaction, which reduces workload, but increases the cost 
of library preparation compared to PCR. 
 
Table 1. Advantages and disadvantages of different viral sequencing methods 
Method Advantages Disadvantages 
Metagenomics  Simple, cost-effective 
sample preparation 




 Effective in ‘fishing’ 
approaches to 
identify a potential 
underlying pathogen 
 High sequencing cost 
to obtain sufficient data 
 Relatively low 
sensitivity to target 
pathogen 
 Coverage proportional 
to viral load 





 Low number of PCR 
cycles causes few 
amplification 
mutations 
 Preservation of minor 
variant frequencies 
reflects in vivo 
variation 
 No primer or probe 
design needed, which 
enables rapid 






 Incidental sequencing 
of human and off-target 
pathogens raises ethical 
and diagnostic issues 
PCR amplification  Tried and trusted –
well-established 
methods and trained 
staff 
 Highly specific – 
most sequencing 




 Highly sensitive, with 
good coverage even 




application of new 
primers for novel 
sequences 
 Labour-intensive and 
difficult to scale for 
large genomes 
 Iterating standard PCRs 
across large genomes 
requires high sample 
volume 
 PCR reactions subject 
to primer mismatch, 
particularly in poorly 
characterised or highly 
diverse pathogens, or 
those with novel 
variants 
 Limited ability to 
sequence novel 
pathogens 
 High number of PCR 
cycles may introduce 
amplification mutations 
 Uneven amplification 
of different PCR 
amplicons may 
influence minor variant 
and haplotype 
reconstruction 
Target enrichment  Single tube sample 
preparation suited to 
high throughput 
automation and 
sequencing of large 
genomes 
 Higher specificity 
than metagenomics 
 High cost and technical 
expertise for sample 
preparation 
 Unable to sequence 






Table 2. Limitations of viral sequencing compared to bacterial sequencing 








Different extraction protocols for different 
viruses, RNA viruses require cDNA 




















Lack of conserved homology between viral 
phyla prevents universal primer based 













a host cell 
for 
replication 
Cultured virus is heavily contaminated 






with cell walls 
can often be 
separated from 







Clinical specimens are heavily 
contaminated with host nucleic acids, 
reducing viral sequencing output 
reduces sequencing 
costs 
 Overlapping probes 
increases tolerance 
for individual primer 
mismatches 






 Preservation of minor 
variant frequencies 
reflects in vivo 
variation 
genomes for probe 
design 
 Sensitivity is 
comparable to PCR but 
coverage is 
proportional to 
pathogen load – low 
pathogen load yields 
low or incomplete 
coverage 
 Cost and time to 
generate new probe sets 
limits rapid response to 























































DNA digestion according to methylation 
patterns is less effective as a means of 
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Sequencing viral DNA and RNA is an important part of clinical practice, although so far mostly 
subgenomic fragements are sequenced. In this Opinion article, Houldcroft, Beale and Breuer, 
highlight the potential that sequencing whole viral genomes has for clinical applications. 
 
